Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow STOK by emailGet an email when STOK pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about STOK, unsubscribe in one click. Privacy
📣 What STOK Says Is Next
second half of 2026 · “Stoke expects a pre-NDA meeting with the FDA in the second half of 2026 and to initiate the rolling NDA process in the first quarter of 2027, with completion expected in the second half of 2027. o Europe (Germany, France, Spain and Italy): An additional cohort of approximately 30 patients is currently being enrolled in Europe, where the sham control is administered via a needle prick (NP).”
Company press release, Aug 3, 2026 · SEC filing
third quarter of 2027 · “Data from this cohort are anticipated in the third quarter of 2027 and are expected to be the final clinical data required to complete the planned rolling NDA submission to the FDA.”
Company press release, Aug 3, 2026 · SEC filing
first half of 2027 · “Dose escalation continues in our Phase 1 study of STK-002 in patients with ADOA and initial data are anticipated in the first half of 2027 to guide future clinical development.”
Company press release, Aug 3, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full STOK picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for STOK and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.